Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $0 versus the consensus estimate of $775 thousand.

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.